Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track

ZEVRA THERAPEUTICS, INC.

Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.
Arimoclomol NDA resubmission for NPC on track by end of 2023; six-month FDA review expected if Type II.
Proposed Acer acquisition (OLPRUVA, EDSIVO) on track for Q4 close; Acer shareholder vote Nov 8, 2023.
Neil McFarlane named President and CEO effective Oct 10, 2023.
Cash $83.4M; cash runway into 2026 includes NDA resubmission and KP1077 program.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZEVRA THERAPEUTICS, INC. reported the quarter ended September 30, 2023 results: revenue Net revenue of $2.9M for Q3 2023.

Period: the quarter ended September 30, 2023
Revenue: Net revenue of $2.9M for Q3 2023
Result: reported results

Exact text from the filing

er 2023 Financial Results Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra ’ s revenue with FDA-approved OLPRUVA ® for urea cycle disorders (UCDs) Net revenue of $2.9M for Q3 2023 Ended Q3 2023 with $83.4M in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 Conference call and live audio webcast scheduled for today, Nov 7, 2023, 8:00 a.m.

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-030485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.